The estimated Net Worth of Kinnary Patel is at least $1.81 Millón dollars as of 29 September 2020. Kinnary Patel owns over 129,400 units of Greenwich LifeSciences stock worth over $1,806,424 and over the last 4 years Kinnary sold GLSI stock worth over $0.
Sign up
Kinnary Patel GLSI stock SEC Form 4 insiders trading
Kinnary has made over 1 trades of the Greenwich LifeSciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Kinnary exercised 129,400 units of GLSI stock worth $1,806,424 on 29 September 2020.
The largest trade Kinnary's ever made was exercising 129,400 units of Greenwich LifeSciences stock on 29 September 2020 worth over $1,806,424. On average, Kinnary trades about 129,400 units every 0 days since 2020. As of 29 September 2020 Kinnary still owns at least 129,400 units of Greenwich LifeSciences stock.
You can see the complete history of Kinnary Patel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kinnary Patel's mailing address?
Kinnary's mailing address filed with the SEC is C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR., BUILDING 14, STAFFORD, TX, 77477.
Insiders trading at Greenwich LifeSciences
Over the last 4 years, insiders at Greenwich LifeSciences have traded over $0 worth of Greenwich LifeSciences stock and bought 654,896 units worth $6,960,565 . The most active insiders traders include Snehal Patel, Kinnary Patel y Kenneth Hallock. On average, Greenwich LifeSciences executives and independent directors trade stock every 16 days with the average trade being worth of $124,412. The most recent stock trade was executed by Snehal Patel on 6 August 2024, trading 2,000 units of GLSI stock currently worth $27,620.
What does Greenwich LifeSciences do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
What does Greenwich LifeSciences's logo look like?
Complete history of Kinnary Patel stock trades at Greenwich LifeSciences
Greenwich LifeSciences executives and stock owners
Greenwich LifeSciences executives and other stock owners filed with the SEC include:
-
Snehal S. Patel,
CEO, CFO & Director -
Snehal S. Patel,
CEO, CFO & Director -
Eric Rothe,
Founder & Independent Director -
Dr. Christine T. Fischette Ph.D.,
VP of Bus. Devel. -
Dr. Jaye L. Thompson Ph.D.,
VP of Clinical & Regulatory Affairs -
Dr. Frank Joseph Daugherty M.D.,
Chief Medical Officer & Director -
Dr. Frank Joseph Daugherty,
Chief Medical Officer & Director -
Snehal Patel,
CEO and CFO -
Kenneth Hallock,
Director -
David Mc Williams,
Director -
Frank Joseph Daugherty,
Chief Medical Officer -
Kinnary Patel,
10% owner -
Jaye Thompson,
VP Clinical Reg Affairs -
Eric Rothe,
Director